<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04592731</url>
  </required_header>
  <id_info>
    <org_study_id>SHEH001</org_study_id>
    <nct_id>NCT04592731</nct_id>
  </id_info>
  <brief_title>Acetylated Natural Nucleotides in Treating Hand-foot Syndrome</brief_title>
  <official_title>A Clinical Trial to Evaluate the Efficacy and Safety of Acetylated Natural Nucleotides in Treating Hand-foot Syndrome (HFS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nan xu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai East Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical trial is planned to investigate the efficacy and safety of acetylated natural&#xD;
      nucleotides in treating anti-cancer medications induced hand-foot syndrome (HFS).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 3, 2020</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients who achieve &quot;NCI CTCAE v5.0 - Palmar-Plantar Erythrodysesthesia (PPE)&quot; grade 0 or 1</measure>
    <time_frame>6 weeks</time_frame>
    <description>The proportion of patients who achieve &quot;NCI CTCAE v5.0 - PPE&quot; grade 0 or 1 at week 6 from grade 2 or above at baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of study drug</measure>
    <time_frame>6 weeks</time_frame>
    <description>Safety of study drug as determined by number of participants with abnormal laboratory values and/or Adverse Events that are related to treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who achieve at least one grade improvement in HFS severity</measure>
    <time_frame>6 weeks</time_frame>
    <description>The proportion of patients who achieve at least one grade improvement in HFS severity according to &quot;NCI CTCAE v5.0 - PPE&quot; by week 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in patient reported pain using Visual Analog Scale (VAS)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change from baseline in patient reported pain using VAS at week 6. VAS is a scale used to determine the pain intensity experienced by individuals, which consists of a line 10 cm in length, with the left side signifying no pain and the right side signifying the worst pain ever.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Hand-Foot Skin Reaction and Quality of Life (HF-QoL) Questionnaire total score</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change from baseline in HF-QoL Questionnaire total score at week 6. HF-QoL questionnaire is comprised of a 20-item symptom domain and an 18-item daily activity domain. Each item is rated on a 5-point scale from 0 (not at all) to 4 (always or extremely) during the previous week. The HF-QoL symptom and daily activity total scores are transformed to a scale of 0 to 100, based on the sum of each unit-weighted item score divided by the maximum score. Higher scores on the HF-QoL indicate worse quality of life or greater symptom burden.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients whose anti-cancer medications are impacted due to HFS</measure>
    <time_frame>6 weeks</time_frame>
    <description>The proportion of patients who need temporary interruption or permanent discontinuation and/or dose reduction of anti-cancer medications due to HFS</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hand-foot Syndrome</condition>
  <arm_group>
    <arm_group_label>Gel containing Acetylated Natural Nucleotides</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gel containing Acetylated Natural Nucleotides</intervention_name>
    <description>The study drug is a gel containing acetylated natural nucleotides.</description>
    <arm_group_label>Gel containing Acetylated Natural Nucleotides</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Gel</intervention_name>
    <description>The vehicle gel contains no acetylated natural nucleotides but with the same base as study drug.</description>
    <arm_group_label>Vehicle Gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older.&#xD;
&#xD;
          -  Pathologically conÔ¨Årmed cancer receiving capecitabine-based anti-cancer therapy&#xD;
             (capecitabine with or without other anti-cancer drugs).&#xD;
&#xD;
          -  With HFS determined by &quot;CTCAE v5.0 - PPE&quot; as grade 2 or above.&#xD;
&#xD;
          -  Able to use topical medications and complete questionnaires reliably with or without&#xD;
             assistance.&#xD;
&#xD;
          -  ECOG performance score &lt; 2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has HFS due to other medications and does not recover within 4 weeks prior to&#xD;
             baseline.&#xD;
&#xD;
          -  Other skin disorders that will affect efficacy evaluation on the hands and feet,&#xD;
             including but not limited to: tinea of feet and hands, hand/foot eczema, palmoplantar&#xD;
             pustulosis, palmoplantar keratosis, acrodermatitis continua etc.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness as determined by the investigator including, but not&#xD;
             limited to, ongoing or active infection, symptomatic congestive heart failure,&#xD;
             unstable angina pectoris, recent myocardial infarction, uncontrolled hypotension or&#xD;
             hypertension, cardiac arrhythmia, or psychiatric illness and social situations that&#xD;
             would limit compliance with study requirements.&#xD;
&#xD;
          -  Significantly abnormal lab test:&#xD;
&#xD;
               -  Inadequate hematologic function as indicated by:&#xD;
&#xD;
                    -  Absolute neutrophil counts (ANC) &lt; 1,500 /mm^3&#xD;
&#xD;
                    -  Hemoglobin (Hgb) &lt; 8.5 g/dL&#xD;
&#xD;
                    -  Platelet count &lt; 75,000 /mm^3&#xD;
&#xD;
                    -  PT or PTT &gt; 1.5 x ULN (if patients on anticoagulants: PT INR &gt; 3.5 x ULN)&#xD;
&#xD;
               -  Inadequate renal and liver function as indicated by:&#xD;
&#xD;
                    -  Albumin &lt; 2.8 g/dL&#xD;
&#xD;
                    -  Total bilirubin &gt; 1.5 x ULN (or &gt; 2.5 x ULN for patients with Gilbert's&#xD;
                       syndrome)&#xD;
&#xD;
                    -  Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and&#xD;
                       alkaline phosphatase &gt; 2 x ULN&#xD;
&#xD;
                    -  Amylase and lipase &gt; 1.5 x ULN&#xD;
&#xD;
                    -  Creatinine &gt; 2 x ULN&#xD;
&#xD;
          -  Any other condition which, in the opinion of the Investigator, would impede&#xD;
             compliance, hinder completion of the study, compromise the well-being of the patient,&#xD;
             or interfere with the study outcomes.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nan Xu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai East Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nan Xu, M.D.</last_name>
    <phone>+86-15520893298</phone>
    <email>xnhrb@aliyun.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai East Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nan Xu, M.D.</last_name>
      <email>xnhrb@aliyun.com</email>
    </contact>
    <investigator>
      <last_name>Nan Xu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 9, 2020</study_first_submitted>
  <study_first_submitted_qc>October 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai East Hospital</investigator_affiliation>
    <investigator_full_name>Nan xu</investigator_full_name>
    <investigator_title>Department Head in Dermatology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hand-Foot Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

